STAT+: An accidental data release by Roche boosts some hopes for anti-TIGIT cancer immunotherapies
The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists. In the wee hours of Wednesday morning, it got…
The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.
Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.
The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.
What's Your Reaction?
